Hos cancerpatienter var den farmakokinetiske profil af Tevagrastim og referenceproduktet sammenlignelige efter en enkelt og gentagne subkutane doser.
In cancer patients, the pharmacokinetic profile of Tevagrastim and the reference product was comparable after single and repeated subcutaneous administration.